Journey Medical Reports Emrosi Shows No Impact on Microbiome in Phase 1 Trial
I'm PortAI, I can summarize articles.
Journey Medical Corporation announced Phase 1 trial results for Emrosi™ (DFD-29), showing no impact on skin, gastrointestinal, and vaginal microbiota in healthy adults. The trial met all primary objectives, indicating Emrosi is well tolerated and supports its use for moderate-to-severe rosacea. Results were published in the Journal of Drugs in Dermatology. This AI-generated news brief is for informational purposes only and not financial advice.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments